KR20240021827A - 미토콘드리아 관련 장애를 치료하는 방법 - Google Patents

미토콘드리아 관련 장애를 치료하는 방법 Download PDF

Info

Publication number
KR20240021827A
KR20240021827A KR1020237043901A KR20237043901A KR20240021827A KR 20240021827 A KR20240021827 A KR 20240021827A KR 1020237043901 A KR1020237043901 A KR 1020237043901A KR 20237043901 A KR20237043901 A KR 20237043901A KR 20240021827 A KR20240021827 A KR 20240021827A
Authority
KR
South Korea
Prior art keywords
subject
methyl
dinitrophenol
disease
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237043901A
Other languages
English (en)
Korean (ko)
Inventor
샤하리야 칸
다이앤 조르카스키
Original Assignee
리부스 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리부스 파마슈티칼스, 인크. filed Critical 리부스 파마슈티칼스, 인크.
Publication of KR20240021827A publication Critical patent/KR20240021827A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237043901A 2021-05-20 2022-05-19 미토콘드리아 관련 장애를 치료하는 방법 Pending KR20240021827A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163191321P 2021-05-20 2021-05-20
US63/191,321 2021-05-20
US202163222841P 2021-07-16 2021-07-16
US63/222,841 2021-07-16
US202263307515P 2022-02-07 2022-02-07
US63/307,515 2022-02-07
PCT/US2022/029992 WO2022246039A1 (en) 2021-05-20 2022-05-19 Methods of treating mitochondria-related disorders

Publications (1)

Publication Number Publication Date
KR20240021827A true KR20240021827A (ko) 2024-02-19

Family

ID=82020295

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043901A Pending KR20240021827A (ko) 2021-05-20 2022-05-19 미토콘드리아 관련 장애를 치료하는 방법

Country Status (14)

Country Link
US (1) US20250177353A1 (https=)
EP (1) EP4340829A1 (https=)
JP (1) JP2024521709A (https=)
KR (1) KR20240021827A (https=)
AU (1) AU2022275935A1 (https=)
BR (1) BR112023024146A2 (https=)
CA (1) CA3219548A1 (https=)
CL (1) CL2023003441A1 (https=)
GE (1) GEAP202416398A (https=)
IL (1) IL308669A (https=)
JO (1) JOP20230298A1 (https=)
MX (1) MX2023013688A (https=)
TW (1) TW202313010A (https=)
WO (1) WO2022246039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150759A1 (en) * 2022-02-07 2023-08-10 Rivus Pharmaceuticals, Inc. Methods of weight loss in a subject with elevated hba1c
TW202515545A (zh) * 2023-08-10 2025-04-16 大陸商深圳君聖泰生物技術有限公司 ２，４－二硝苯酚之衍生物以及前藥、以及其組成物以及方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo

Also Published As

Publication number Publication date
EP4340829A1 (en) 2024-03-27
JP2024521709A (ja) 2024-06-04
CL2023003441A1 (es) 2024-05-10
JOP20230298A1 (ar) 2023-11-19
US20250177353A1 (en) 2025-06-05
TW202313010A (zh) 2023-04-01
WO2022246039A1 (en) 2022-11-24
AU2022275935A1 (en) 2023-12-07
BR112023024146A2 (pt) 2024-01-30
CA3219548A1 (en) 2022-11-24
MX2023013688A (es) 2024-02-27
GEAP202416398A (en) 2024-01-25
IL308669A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
Zambrowicz et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes
KR20220070057A (ko) 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
JP2024529452A (ja) 長時間作用型ｇｌｐ１／グルカゴン受容体アゴニストのための投薬レジメン
US20210283105A1 (en) Novel regimes of fxr agonists
KR20240021827A (ko) 미토콘드리아 관련 장애를 치료하는 방법
TW202210097A (zh) 用於治療肝臟疾病之組合療法
TW201215392A (en) Use of ranolazine for treating pulmonary hypertension
US20250134864A1 (en) Methods of weight loss and preserving skeletal muscle mass
US20210000792A1 (en) Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
US20250134865A1 (en) Methods of weight loss in a subject with elevated hba1c
CN117881399A (zh) 治疗粒线体相关病症的方法
WO2019099509A1 (en) Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
CN118900692A (zh) HbA1c升高的受试者的体重减轻方法
Gninkoun et al. Fatty liver linked to reduced frequency of ocular complications in T2DM
CN118922187A (zh) 体重减轻和保持骨骼肌量的方法
TW202500575A (zh) 具有或不具有體重相關合併症之過重或肥胖成人之治療
KR20260055436A (ko) 심부전 치료용 화합물 azd5462
Kim et al. PP. LB03. 15: SERUM GAMMA-GLUTAMYLTRANSFERASE LEVELS ARE ASSOCIATED WITH CONCOMITANT CARDIOVASCULAR RISK FACTORS IN KOREAN HYPERTENSIVE PATIENTS

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250516

Comment text: Request for Examination of Application